Le Lézard
Classified in: Health
Subjects: TDS, PET, FVT

Kindred Biosciences to Present at the Oppenheimer 28th Annual Healthcare Conference



SAN FRANCISCO, March 8, 2018 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, will present at the Oppenheimer 28th Annual Healthcare Conference on March 20-21, 2018 in New York City.

Kindred Biosciences, Inc. Logo

Denise Bevers, Co-Founder and Chief Operating Officer, will present and be available for one-on-one meetings at which investors will have the opportunity to discuss key therapeutic programs in development and upcoming milestones.

Presentation Details:

Date: Wednesday, March 21, 2018

Time: 2:10 - 2:40 PM EDT (11:10 - 11:40 AM PDT)

Location: The Westin New York Grand Central, Track 61 room

Webcase URL:  https://www.veracast.com/webcasts/opco/healthcare2018/15212424202.cfm

An archived version of the webcast will be available for 30 days on the Company's website: http://kindredbio.com/investor-relations/events/.

About Kindred Biosciences

Kindred Biosciences is a pre-commercialization stage biopharmaceutical company focused on saving and improving the lives of pets. Its mission is to bring to pets the same kinds of safe and effective medicines that human family members enjoy. The Company's strategy is to identify compounds and targets that have already demonstrated safety and efficacy in humans and to develop therapeutics based on these validated compounds and targets for dogs, cats and horses. The Company has a deep pipeline of novel drugs and biologics in development across many therapeutic classes.

For more information or to download the corporate presentation, visit www.KindredBio.com/LearnMore. Stay connected with KindredBio on Facebook at www.Facebook.com/KindredBio.

Contact
Russell Radefeld
KindredBio
russell.radefeld@kindredbio.com
(650) 701-7904

 

SOURCE Kindred Biosciences, Inc.


These press releases may also interest you

at 19:00
ROCKVILLE, Md., Sept. 21, 2018 /PRNewswire-PRWeb/ -- - Bharti Shah, Chief Executive Officer CTIS, Inc., Rockville, MD based Health Informatics company, today announced the promotion of Ms. Bharti Shah to Chief Executive Officer. She will have the...

at 18:15
Pharmaceutical startup Bridge Therapeutics announces the addition of Dr. Bob Raffa as its newest Scientific Advisory Board member. "We are delighted to have Dr. Raffa join our scientific advisory board. His research on pain and addiction medications...

at 18:00
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from a Phase 3 clinical study of the investigational product esketamine nasal spray in patients with treatment-resistant depression. Janssen researchers presented these...

at 17:45
The "Global Burkitt Lymphoma Therapeutics Market 2018-2022" report has been added to ResearchAndMarkets.com's offering. The Global Burkitt Lymphoma Market to grow at a CAGR of 3.07% during the period 2018-2022. Burkitt lymphoma market 2018-2022,...

at 17:30
The "Global ELISA Workstation Market 2018-2022" report has been added to ResearchAndMarkets.com's offering. About ELISA Workstation An ELISA workstation comprises a pipetting system, washer, shaker, incubator, and reader along with a provision for...

at 17:00
Namaste Technologies Inc. ("Namaste" or the "Company") is pleased to announce that the Company's wholly-owned subsidiary, Cannmart Inc. ("Cannmart") has received its Access to Cannabis for Medical Purposes Regulations ("ACMPR") medical cannabis...




News published on 8 march 2018 at 16:01 and distributed by: